Search page

5.5 Years of Long-Term Efficacy of Oral Berotralstat-LTP in Hereditary Angioedema Patients

A Phase 3 Open-Label Trial-In-Progress Evaluating Garadacimab For Prophylactic Treatment Of Pediatric Patients (Aged 2–11 Years) With Hereditary Angioedema

A first structured diagnostic approach to identify underlying diseases of patients with acquired angioedema

A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden

A predictive model to differenciate chronic histaminergic angiodema and chronic spontaneous urticaria with angioedema

A sensitive and specific assay to characterize plasma kallikrein activity in plasma from hereditary angioedema (HAE) patients

Achieving the goals of hereditary angioedema treatment (HAE)

Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series

Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US

Advances in Histaminergic Angioedema

Advancing Diagnosis and Management of Hereditary Angioedema in Brazil: Insights from the first 704 patients of a Multicenter Registry

Adverse Health Outcomes and Patient and Physician Perspectives of Attenuated Androgen Use in Hereditary Angioedema

An Incomplete Acquired Angioedema In a 84-Year-Old Patient: Case Report

Analysis of prodromal symptoms and need for short-term prophylaxis in hereditary angioedema patients under long-term prophylaxis

Angioedema due to acquired C1-inhibitor deficiency and lymphoid hemopathies

Angioedema due to acquired C1-inhibitor deficiency associated to monoclonal gammopathies of undetermined significance – Characteristics of a French national cohort

Angioedema in childhood: with or without urticaria

Anxiety Associated with On-Demand Treatment for Hereditary Angioedema Attacks

Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy

Artificial Intelligence Driven Approaches to Endotype Patients with Recurrent Angioedema

Attack-free Rates and Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-androgen Long-term Prophylaxis

Attack-free probability modeling of garadacimab long-term prophylaxis for hereditary angioedema

Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study

BioCryst – Reimagining hereditary angioedema (HAE) care – is it time to define the new ‘normal’ for patients with HAE?

Breakthroughs in management of Hereditary Angioedema

Burden Of Hereditary Angioedema and Impact on Quality Of Life: Final Data From a Multinational Patient Survey

Burnout and Stress in Angioedema Care: Insights from a Multicenter Observational Study MENPHYS

C1 inhibitor deficiency: a long road from the diagnosis of possible hereditary angioedema to the diagnosis of splenic marginal zone lymphoma

CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks

Case report of a patient with C1-inhibitor acquired angioedema and prostate cancer treated with Lanadelumab relayed by Berotralstat

Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)

Changes in the attacks’s frequency during Lanadelumab treatment in patients with hereditary angioedema from Romania

Characteristics of Nailfold Videocapillaroscopy in Hereditary Angioedema due to C1 Inhibitor Deficiency

Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Classification of patients with hereditary angioedema

Clinical Course of Hereditary Angioedema Patients Transitioning off Androgens

Clinical Impact of Long-Term Prophylaxis De-escalation with Lanadelumab in Hereditary Angioedema Type I and II

Clinical Outcomes Of Dental Procedures In Patients With Hereditary Angioedema

Clinical Validation of a Novel Kinin Biomarker Assay for Characterisation of Bradykinin-Mediated Pathologies in US Subjects with Hereditary Angioedema

Clinical and laboratory features of patients with non-hereditary angioedema – a preliminary report of 37 cases

Clinical characteristics and unmet treatment need in patients with hereditary angioedema treated with long-term prophylaxis: A real-world survey

Clinical features and Progress of Diagnosis and Therapy of Hereditary Angioedema in China: A Systemic Review of Published Cases

Clinical profile and management of pediatric hereditary angioedema in resource constrained settings: our experience from a single centre in North India

Comorbidities in hereditary angioedema patients in Canada: a quantitative survey study

Comparison of Component Resolved Diagnosis (CRD) with skin prick test in respiratory allergy [36 cases] and Significance of CRD in Anaphylaxis [8 cases] & Chronic Urticaria with/ without Angioedema [16 cases]

Comparison of baseline clinical characteristics of chronic spontaneous urticaria patients receiving omalizumab, with and without concomitant angioedema

Complement activation during erythema marginatum in patients with hereditary angioedema

Correlation Between Subjective and Objective Disease Control in Hereditary Angioedema: Association Between the Angioedema Control Test and Attack Rate

Correlation of chronic urticaria and angioedema with the presence of Helicobacter pylori infection

Cross-talks between mast cells and bradykinin.: implications in angioedema pathophysiology

Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers

Demographic, clinical, and genetic characterization of patients with hereditary angioedema due to mutation in coagulation factor XII in a population of southern Spain

Description of Clinical Features and Triggers in Hereditary Angioedema Attacks Associated with Coagulation Factor XII Mutations

Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency

Difficult to control hereditary angioedema during pregngancy

Drug-induced angioedema by racecadotril in a patient treated with angiotensin-converting enzyme inhibitors

Drug-induced non IgE mediated angioedema

EAACI Highlight Plenary session Focus on Angioedema and Mast Cell Diseases

Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Effectiveness and safety of berotralstat in patients with hereditary angioedema with normal C1-inhibitor: A European case series

Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Subanalysis of the Phase 3 OASIS-HAE Study

Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design

Efficacy of lanadelumab on attack frequency and AE-QoL in Serbian patients with hereditary angioedema

Elucidating the pathogenesis of hereditary angioedema through advanced genetic sequencing and single-cell sequencing analyses

Evaluation of Anxiety, Depression, and Death Anxieties in Patients Diagnosed with Hereditary Angioedema

Evolution in Acute Management of Hereditary Angioedema due to C1 inhibitor deficiency (HAE-C1INH)

Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)

Evolution of health-related quality of life and disease control during the first year of Lanadelumab treatment in Romanian patients with Hereditary Angioedema due to C1-inhibitor deficiency

Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema

Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data

F12 c.983C>A gene variant is the predominant cause of hereditary angioedema with normal C1 inhibitor among Peruvian patients

Facial angioedema

Flash talks on Angioedema

Flash talks on Hereditary Angioedema

From angioedema to Kimura disease: Diagnostic challenge

Gene Sequencing of Angioedema with Normal C1-INH in Israel

Genetic Studies in Angioedema

Genetic study in patients with hereditary angioedema due to mutation in coagulation factor XII in a population of southern Spain

Genetic variant spectrum of SERPING1 gene in 46 families residents of Southern Spain with hereditary angioedema with C1-INH deficiency (HAE-C1-INH). Identification of 11 novel variants

Genital Attacks in Hereditary Angioedema And Their Effects On Sexual Life

Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone

Health-related quality of life in hereditary angioedema patients using subcutaneous plasma derived C1 inhibitor therapy in Canada

Healthcare Provider Burden associated with the treatment of attacks in patients with hereditary angioedema in Latin America: A Pilot Study

Hereditary Angioedema

Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?

Hereditary Angioedema Attack Diary Determination of the Effect of Mobile Application on Patients’ Quality of Life and Treatment Compliance Level

Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health

Hereditary Angioedema Type I in a 57-Year-Old Woman

Hereditary Angioedema in A Portuguese Paediatric Population

Hereditary Angioedema in Bulgaria: an update on patient characteristics and treatment modalities

Hereditary Angioedema with Normal C1 Inhibitor: Novel Genetic Mutations and Insights from a Large Genomic Cohort Study

Hereditary angioedema and severe chronic urticaria, what the odds?

Hereditary angioedema caregiver burden. Data from the 2020 Canadian national survey

Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Hereditary angioedema with normal C1-Inhibitor: A series of 41 genetically characterized patients from Northern Portugal

Hereditary angioedema with normal C1-inhibitor level or Melkerson-Rosenthal syndrome?- response to the treatment: A case report

Hereditary angioedema with normal C1Inh and PLG mutation treated with tranexamic acid : Beware of the risk of thrombosis

How to differentiate histaminergic from bradykinergic angioedema

How to identify acquired angioedema with low C1-inhibitor

Identification of candidate biomarkers for diagnosing and assessing the disease severity of type 2 hereditary angioedema via plasma N-glycomics

Idiopathic angioedema due to acquired C1-inhibitor deficiency: a multicenter French cohort study of 34 patients

Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States

Impact of hereditary angioedema on dental care: from a study of 112 French patients

Importance of non-itchy erythema marginatum as a prodromal symptom of hereditary angioedema attacks

Improvements in Quality of Life in Patients With Hereditary Angioedema Receiving Donidalorsen: Post Hoc Analysis From the OASIS-HAE Study and Results From the OASISplus Open-Label Extension

In Hereditary Angioedema Attack Urinary System Involvement and Hydronephrosis

Inflammatory and kallikrein-kinin serum profiling of acute ACE-inhibitor angioedema

Initial description of a patient with a new plasminogen mutation who exhibits symptoms consistent with hereditary angioedema

Innovations in angioedema diagnosis

Insights into Hereditary Angioedema management

Interoceptive sensibility and body appreciation in patients affected by Hereditary Angioedema

Isolated and recurrent eyelid angioedema in an 8-year-old girl

Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience

Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Laryngeal Edema-Related Mortality in Hereditary Angioedema Patients: Insights from Verbal Autopsy Findings Obtained from Relatives

Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema

Long-Term Durability of CRISPR-Based Gene Editing of KLKB1 From Phase 1 of a Phase 1/2 Trial of Patients With Hereditary Angioedema

Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants With Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Long-term efficacy of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis

Long-term prophylaxis with first line therapies in patients with hereditary angioedema with C1 inhibitor deficiency, real-life experience

Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis

Management of recurrent angioedema beyond HAE-C1INH

Managing Skin Allergies: Urticaria, Dermatitis, and Angioedema

Mast cell mediated angioedema without wheals: Is It urticaria or not?

News in hereditary angioedema management

Nitial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: a Clinical Observation

Omalizumab as a diagnostic and therapeutic trial for recurrent idiopathic angioedema

Online Education Significantly Improves Physicians’ Knowledge of Novel Long-Term Prophylaxis Therapies for Hereditary Angioedema

Online Education Yields Significant Gains in Physicians’ Knowledge of the Latest Data with Emerging Therapies for Hereditary Angioedema

Patients with hereditary angioedema in Belarus: data from the National registry of primary immunodeficiency disorders

Phenotypes of patients with Hereditary Angioedema (HAE): a case series

Pregnancy, birth and postpartum follow-up of a Factor 12 Hereditary Angioedema patient with Familial Mediterranean Fever

Prevalence of Sleep Disorders in Patients with Hereditary Angioedema

Prevalence of angioedema in the emergency department at Sant Joan De Déu (Manresa)

Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)

Proactive identification of rare diseases: Lessons from hereditary angioedema diagnosis using electronic medical records

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema

Prophylaxis with androgens can cause liver cancer in patients with Hereditary Angioedema

Prospective monitoring of clinical outcomes and laboratory markers of hereditary angioedema in patients on long-term prophylaxis with lanadelumab: One-year follow-up

Rare cause of angioedema

Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)

Real-World Effectiveness and Safety of Lanadelumab for Hereditary Angioedema Attack Prophylaxis: A 3-Year Interim Analysis of the ENABLE Study

Real-life features of hereditary angioedema attacks: first results from the registry supported by ITACA (Italian network for hereditary and acquired angioedema)

Recurrent Uvular Angioedema After Intranasal Cocaine Use

Recurrent angioedema with normal C1-inhibitor: the key task to distinguish the endotypes

Recurrent angioedema with the mutation in the Myoferlin gene. Clinical observations

Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies

Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Results related to the implementation of a transdisciplinary care model in patients diagnosed with hereditary angioedema

Retrospective evaluation of the prevalence of autoimmunity in patients with hereditary angioedema

Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study

Selective Facial Angioedema Induced by Propionic Acids: A Clinical Study of NSAID Idiosyncratic Reactions (Type 3a)

Severe asthma associated with hereditary angioedema type 1 and other pathologies

The Clinical Faces of Hereditary Angioedema

The Determinants of Acute Attack Development in Hereditary Angioedema Patients Undergoing Dental Interventions

The Effect of Surgical and Interventional Procedures on Attack Frequency in Hereditary Angioedema Patients

The Silent Threat of Hereditary Angioedema in Children: Single Center Experience

The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States

The importance of individualizing in the choice of prophylaxis for hereditary angioedema

Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment

Under-representation and -reporting of race in global hereditary angioedema trials: A hidden yet alarming source of disparities

Understanding the pathophysiology of hereditary angioedema (HAE) using a personalized expanded potential stem cell (EPSC) platform

Understanding treatment switching patterns and continuation rates for patients with hereditary angioedema receiving lanadelumab: analysis of real-world data

Urticaria and Angioedema

Using data from the National Health Registries to estimate the burden and medication usage in Hereditary Angioedema in Colombia

Abdominal angioedema attacks, an unusual location in a patient with mast-cell mediated angioedema

Demographic and diagnostic features of hereditary angioedema patients due to C1 inhibitor deficiency: a large cohort from the Italian network for hereditary and acquired angioedema (ITACA) Registry

Migraine-like headache and quality of life in hereditary angioedema due to C1-inhibitor deficiency: first evidence from the Italian Network for Hereditary and Acquired Angioedema (ITACA)

Prediction of a hereditary angioedema attack in patients with recurrent angioedema: awareness at a glance with the hereditary angioedema prediction score (HAEps)

Triggers and prodromal indicators of angioedema attacks in hereditary angioedema patients

Turkish National Hereditary Angioedema and Acquired Angioedema Registry, Established to Encourage Standardizing the Care and Management of the Disease. HAE/AAE-TR National Hereditary and Acquired Angioedema Registry Group

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Event Resources

Courses

Sponsored Symposia

Covid-19

Guidelines

Website

Sessions

Working groups